Sitagliptin malate is used to treat type 2 diabetes mellitus. It functions as a DPP-4 (dipeptidyl peptidase-4) inhibitor, similar to sitagliptin hydrochloride, and helps improve blood sugar control by increasing incretin levels. These incretins boost insulin secretion and reduce glucagon release in response to meals, leading to better glucose regulation. The malate salt form is used to enhance the drug’s stability or solubility but does not change its therapeutic effect. Sitagliptin malate is often used alone or with other antidiabetic drugs like metformin. It is grouped under the following drug class(es): DPP-4 inhibitors and Hypoglycemics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Sitagliptin L-malate and UNII-6Q9M3E3GG7. Its PubChem CID is 163203575.
Sitagliptin malate
| CAS No | 1240039-02-4 |
|---|---|
| Molecular Formula | C20H21F6N5O6 |
| Molecular Weight | 541.4 g/mol |
| Synonyms | (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one;(2S)-2-hydroxybutanedioic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Sitagliptin malate is used to treat type 2 diabetes mellitus. It functions as a DPP-4 (dipeptidyl peptidase-4) inhibitor, similar to sitagliptin hydrochloride, and helps improve blood sugar control by increasing incretin levels.
The listed CAS number is 1240039-02-4.
The listed molecular formula is C20H21F6N5O6.
The listed molecular weight is 541.4 g/mol.
(3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one;(2S)-2-hydroxybutanedioic acid.
The source lists Sitagliptin L-malate and UNII-6Q9M3E3GG7.